Single Session Y90 TARE: Improving Efficiency in Hepatocellular Carcinoma Care

Abstract Hepatocellular carcinoma is a leading cause of cancer-related mortality, and trans-arterial radioembolization (TARE) with yttrium-90 (Y90) has emerged as an effective therapy for unresectable and select early-stage disease. Conventional TARE requires a two-stage workflow with technetium-99m macroaggregated albumin mapping to evaluate vascular anatomy and lung shunt fraction (LSF), followed by treatment delivery 2 to 4 weeks later. Although safe and effective, this approach introduces logistical barriers, treatment delays, and additional costs. Recently, single-session Y90 TARE has shown promising technical and clinical success rates, with safety comparable to conventional TARE. By streamlining care, single-session Y90 TARE reduces procedure time, hospital resource use, and patient burden. This review highlights the safety, efficacy, and future directions of single-session Y90 TARE.